Abstract 501P
Background
Previous studies have proved that EGFR exon 20 insertion (EGFRex20ins) mutation present in about 1.8% of non-small cell lung cancer (NSCLC). 22% of EGFRex20ins are co-occurring with EGFR amplification. The aim of this study is to investigate the clinical characteristics and efficacy in Chinese NSCLC patients harboring EGFRex20ins and EGFR amplification.
Methods
A total of 1483 patients with advanced NSCLC were screened. All variants of EGFRex20ins and other oncogenic drivers were identified by next-generation sequencing (NGS).
Results
EGFRex20ins were found in 2.2% of patients and a total of 38 patients were included in clinical characteristics analysis. Various EGFRex20ins were identified, most commonly V769_D770dup (26.3%) and D770_N771dup (23.7%). Interestingly, co-occurring EGFR amplification was found in 39.5% of patients (15/38). In patients with EGFR amplification, the median age was 58 years (range, 38 to 75 years), and 66.7% were female. Most of them were never-smokers (86.7%) and had adenocarcinoma (93.3%). These clinical characteristics were not significantly different from those without EGFR amplification (P > 0.05). Except for patients with EGFR-sensitive mutations, a total of 25 patients who had used EGFR-tyrosine kinase inhibitors (TKIs) were included in the survival analysis. Although there were no statistically differences in two group, a tendency of prolonged median progression-free survival (mPFS) in patients without EGFR amplification was found (80.5 versus 30.0 days, P = 0.175).
Conclusions
EGFR amplification often co-occur with EGFRex20ins in Chinese NSCLC, and the ratio is higher than previous studies in Caucasian. Although there was no difference in clinical characteristics and efficacy between patients with and without EGFR amplification, a tendency of prolonged mPFS in patients without EGFR amplification was found. Future prospectively large-sample-size studies are needed to evaluate this finding.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Guangdong Lung Cancer Institute.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)
Presenter: Yusuke Sasaki
Session: Poster display session
Resources:
Abstract
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract